Key Pharma News Issue - 2016 Global Oncology Pipeline To Benefit From Breaking Innovation Barriers - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Key Pharma News Issue 49" report to their offering.

As the sector is targeted for long-term growth, oncology's high potential gains will continue to draw investment in 2016. Action taken in 2015 will induce deep pipeline shifts as multinationals seek to mitigate losses from ageing portfolios. The fast moving environment requires very high levels of innovation. In order to meet these criteria, open innovation avenues will increasingly be explored.

Key Topics Covered:

1. Agreements

  • Amgen Reacquires Rights To Prolia/Xgeva/Vectibix From GSK
  • Halozyme Enters Into Global Collaboration And Licensing Agreement With Eli Lilly

2. Corporate Activity

  • ViiV Healthcare To Buy BMS' HIV R&D Assets
  • Western Europe Poised To Become Krka's Most Important Region
  • Sanofi/BI Enter Exclusive Negotiations On Business Swap
  • Acquisition Battles Dominated Generic Industry In 2015 And Will Shape It In
  • Galapagos/Gilead To Co-Develop Filgotinib For Inflammatory Diseases
  • Compliance Will Be Key In Future CNS Medication
  • AstraZeneca Acquires ZS Pharma
  • Samsung BioLogics To Construct Biopharmaceutical Manufacturing Plant In Songdo
  • Eisai Completes Liaoning TianYi Biological Pharmaceutical Acquisition

3. Product News

  • EC Approves Amgen's Imlygic As First Oncolytic Immunotherapy
  • Alecensa Approved In US For ALK-Positive NSCLC
  • Dengvaxia To Experience Swift Initial Uptake
  • Amgen Submits Biosimilar Adalimumab MAA To EMA
  • US Biosimilar Market Set To Take Off In
  • FDA Approves Basaglar For Diabetes
  • TWi Gains Megestrol Appellate Court Victory
  • Sun Gains US Imatinib Approval
  • Actelion Gains US Uptravi Approval For PAH
  • FDA Approves Zurampic For Gout

4. R&D

  • HBV To Join HCV As Lead Anti-infective Focus In
  • Commercial Opportunities In Breast Cancer Remain
  • Novartis Maintaining CAR-T Lead
  • Successful Ofev And Esbriet Trial Results Will Lock Down IPF Market
  • 2015 Trends In Alzheimer's Disease

For more information visit http://www.researchandmarkets.com/research/bq2jhj/key_pharma_news

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals